IntelliPharmaCeutics International (IntelliPharmaCeutics International) 3-Year EBITDA Growth Rate : 40.00% (As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International 3-Year EBITDA Growth Rate?

IntelliPharmaCeutics International's EBITDA per Share for the three months ended in Aug. 2023 was $-0.05.

During the past 3 years, the average EBITDA Per Share Growth Rate was 40.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 54.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 32.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of IntelliPharmaCeutics International was 67.80% per year. The lowest was -45.00% per year. And the median was 3.85% per year.

Competitive Comparison of IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate falls into.

IntelliPharmaCeutics International 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

IntelliPharmaCeutics International (OTCPK:IPCIF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

IntelliPharmaCeutics International 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.